Aurora Cannabis reported a 7% increase in total net revenue to $94.2 million for Q3 2026, primarily driven by a record 12% growth in global medical cannabis net revenue to $76.2 million. The company achieved an adjusted EBITDA of $18.5 million and generated $15.5 million in free cash flow, while maintaining a strong balance sheet with $154.4 million in cash and short-term investments.

Aurora Cannabis delivered record medical cannabis revenue in Q2 2026 and achieved 52% growth in adjusted EBITDA, but posted a significant net loss due to impairments and rising expenses.

Aurora Cannabis delivered a 34% year-over-year increase in net revenue in Q4 2025, driven by international medical cannabis sales and improved margins. Despite a net loss, adjusted EBITDA grew substantially, and the company generated positive free cash flow.